About: Inhibition of hepatitis B virus replication by ligand-mediated activation of RNase L

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Inhibition of hepatitis B virus replication by ligand-mediated activation of RNase L Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Inhibition of hepatitis B virus replication by ligand-mediated activation of RNase L
Creator	Ryu, Wang-Shick Ahn, Byung-Yoon Kwon, Young-Chan Park, Il-Hyun
Source	Elsevier; Medline; PMC
abstract	Abstract RNase L is a cellular endoribonuclease that is activated by 2′,5′-linked oligoadenylates (2–5A), which are unique and specific ligands synthesized by a family of interferon-inducible, dsRNA-activated enzymes named oligoadenylate synthetases. In the typical antiviral pathway, activated RNase L degrades viral and cellular RNAs, thus limiting viral replication and spread. Although the antiviral activity of RNase L has been demonstrated for several RNA viruses, there is little evidence regarding its role against DNA viruses. In the present study, the potential antiviral activity of RNase L against hepatitis B virus (HBV) was explored utilizing the recently reported infection protocol based on human hepatoma HepG2 cells stably complemented with the virus entry factor NTCP. Viral replication and expression in this cell type was markedly inhibited by poly(I:C)- or 2–5A-mediated activation of RNase L; however, the inhibition was significantly reversed by RNase L knockdown. Further analysis in HBV1.2-transfected Huh-7 hepatoma cells indicated that the antiviral activity of RNase L depends on its ribonuclease function. We also provide evidence for the specific roles of OAS family members in this process. These results suggest that HBV replication can be regulated through interferon-mediated RNA decay pathways and that activation of these host antiviral factors may represent a novel therapeutic strategy for HBV infection.
has issue date	2014-04-30(xsd:dateTime)
bibo:doi	10.1016/j.antiviral.2014.01.021
bibo:pmid	24509240
has license	els-covid
sha1sum (hex)	ea51549ce92908ddc1d509a2269e512a83dfb54b
schema:url	https://doi.org/10.1016/j.antiviral.2014.01.021
resource representing a document's title	Inhibition of hepatitis B virus replication by ligand-mediated activation of RNase L
has PubMed Central identifier	PMC7119188
has PubMed identifier	24509240
schema:publication	Antiviral Research
resource representing a document's body	covid:ea51549ce92908ddc1d509a2269e512a83dfb54b#body_text
is schema:about of	named entity 'RNAs' named entity 'reversed' named entity 'HBV' named entity 'cell type' named entity 'ribonuclease' named entity 'hepatitis B virus' named entity 'Inhibition' named entity 'RNASE L' named entity 'HEPATITIS B VIRUS' named entity 'VIRUS REPLICATION' named entity 'UNIQUE' named entity 'POTENTIAL' named entity 'HEPG2' named entity 'FAMILY' named entity '28I' named entity 'MARKEDLY' named entity 'INDICATED' named entity 'RNA VIRUSES' named entity 'HOST' named entity 'FUNCTION' named entity 'ACTIVATED' named entity 'VIRUS ENTRY' named entity 'RESULTS' named entity 'REGULATED' named entity 'INDUCIBLE' covid:arg/ea51549ce92908ddc1d509a2269e512a83dfb54b named entity 'INFECTION PROTOCOL' named entity 'HUMAN' named entity 'POLY' named entity 'ENDORIBONUCLEASE' named entity '2-5A' named entity 'INHIBITION' named entity 'ROLES' named entity 'REPORTED' named entity 'DEMONSTRATED' named entity 'LITTLE' named entity 'CELLULAR' named entity 'ROLE' named entity 'HEPATOMA CELLS' named entity 'FACTOR' named entity 'PROCESS' named entity 'HBV' named entity 'HBV INFECTION' named entity 'SPREAD' named entity 'DSRNA' named entity 'RNAS' named entity 'CELLS' named entity '2C5' named entity 'INHIBITED' named entity 'OLIGOADENYLATE' named entity 'THERAPEUTIC' named entity 'EXPRESSION' named entity 'ENZYMES' named entity 'SYNTHESIZED' named entity 'REPRESENT' named entity 'NAMED' named entity 'STRATEGY' named entity 'STUDY' named entity 'MEDIATED' named entity 'SUGGEST' named entity 'LIGANDS' named entity 'ITS' named entity 'SPECIFIC' named entity 'TYPICAL' named entity 'LIGAND' named entity 'RNASE L' named entity 'RECENTLY' named entity 'REVERSED' named entity 'SYNTHETASES' named entity 'PROVIDE' named entity 'EVIDENCE' named entity 'ACTIVATION' named entity 'INHIBITION' named entity 'PRESENT' named entity 'ACTIVATION' named entity 'REPLICATION' named entity 'NTCP' named entity 'HEPATOMA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software